Nventa strengthens patent portfolio with two new European Patents for HPV-related diseases
Nventa Biopharmaceuticals Corporation announced that the European Patent Office has granted two patents to Nventa related to HspE7, its investigational therapeutic vaccine for the treatment of human papillomavirus (HPV)-related diseases. HspE7 consists of a heat shock protein (Hsp) covalently fused to an HPV E7 viral protein to form one CoVal(TM) therapeutic protein.
Patent Number EP 1,296,711 B1, "HPV E7 For Human Papilloma Virus Treatment," covers the use of Nventa's HPV-16 based CoVal(TM) fusion protein HspE7, for the treatment of HPV-related diseases not caused by HPV-16. The patent addresses and provides Nventa protection around observations made from earlier studies that show clinically relevant responses in diseases such as genital warts.
Patent Number EP 1,336,621 B1, "Immune Responses Against HPV Antigens Elicited by Compositions Comprising HPV Antigens and Stress Proteins or an Expression Vector Capable of Expression of These Proteins," provides further coverage for HspE7 with specific claims for the composition of Hsp-HPV E7 fusion proteins and their use for manufacturing drugs that induce an immune response against HPV protein antigens.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.